FDA Committee Endorses Treatments for Breast Cancer, Sickle Cell Disease

Drug Industry Daily
A A
An FDA advisory committee recommended Wednesday that the agency approve two NDAs, one in breast cancer and one in sickle cell disease.

To View This Article:

Login

Subscribe To Drug Industry Daily